Users of HSRIC information

National Institute for Health Research (NIHR) research programmes

The NIHR HSRIC sent information on emerging health technologies that may benefit from additional research to the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC). NETSCC coordinates and manages several research programmes including the Health Technology Assessment (HTA) and the Efficacy and Mechanism Evaluation (EME) programmes. Other NIHR research programmes that receive information from the NIHR HSRIC include the Invention for Innovation programme managed by the NIHR Central Commissioning Function.


National Institute for Health & Care Excellence (NICE)

HSRIC aimed to notify the topic selection team at NICE about emerging drugs and advanced therapy medicinal products (ATMPs) and new indications for already licensed products, around 20 months and 15 months before launch into the NHS respectively. HSRIC aimed to provide information on innovative medical devices and diagnostics to NICE medical technologies evaluation and diagnostic assessment programmes (MTEP and DAP) up to 24 months prior to commercial availability in the NHS.


NHS England

Emerging drugs and ATMPs identified at the filtration stage for very small patient groups were also sent to the NHS England specialised services team for consideration.

Other users included policy makers in Scotland, Wales and Northern Ireland,; the UK National Screening Committee and programmes; NICE Interventional Procedures Programme; Public Health England; wider NHS commissioners and providers, health professionals and patients; and the international health technology assessment (HTA) community.